Tesaro — Q3 2013 Earnings Presentation
24 slides from Tesaro's earnings presentation, Nov 7, 2013
Slide 1: Third-Quarter Operating Results
Third-Quarter Operating Results November 7, 2013
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical facts are forward-looking statements reflecting the current beliefs and expectations of management. Forward-looking statements are sometimes identified by words such as “plan,” “may,
Slide 3: Lonnie Moulder, Chief Executive Officer
Lonnie Moulder Chief Executive Officer
Slide 4: Ted English, VP Finance & Administration
Ted English Vice President, Finance & Administration
Slide 5: Q3 2013 Financial Results
Q3 2013 Financial Results Three Months Ended September 30, 2013 Three Months Ended September 30, 2012 Expenses: Research & Development $22,163 $11,876 General & Administrative 4,503 1,736 Acquired In-process R&D 1,940 -- Total Expenses 28,606 13,612 Loss from Operations (28,606) (13,612) Interest In
Slide 6: Mary Lynne Hedley, Ph.D., President
Mary Lynne Hedley, Ph.D. President
Slide 7: A Balanced Portfolio of Product Candidates
MEC: Moderately Emetogenic Chemotherapy; HEC: Highly Emetogenic Chemotherapy; CINV: Chemotherapy-Induced Nausea & Vomiting A Balanced Portfolio of Product Candidates Compound Indication Pre-clinical Phase 1 Phase 2 Phase 3 Rolapitant Oral (NK-1 receptor antagonist) CINV in HEC treated patients CINV
Slide 8: Development Programs Update
SARC: Sarcoma Alliance for Research through Collaboration Development Programs Update Phase 3 NOVA trial continues to enroll patients Phase 3 BRAVO trial now screening patients Collaborating with SARC for Ewing’s sarcoma Niraparib Initial Phase 1 data presented at the European Cancer Congress and 15
Slide 9: Ovarian Design and Objectives
Ovarian Design and Objectives 360 patients with high grade serous ovarian cancer (HGSOC) Platinum sensitive, relapsed Two independent cohorts: gBRCAmut and non-gBRCAmut Overview Randomized, international study Each cohort is independently randomized 2:1 niraparib to placebo; powered separately Daily
Slide 10: Breast Design and Objectives
Breast Design and Objectives ~300 patients with gBRCAmut and advanced/metastatic Prior anthracycline/taxane Up to 2 treatments for advanced/metastatic disease Overview Randomized, international study Independently randomized 2:1 niraparib to investigator choice [eribulin, capecitabine, gemcitabine o
Slide 11: Development Programs Update
Development Programs Update Phase 3 NOVA trial continues to enroll patients Phase 3 BRAVO trial now screening patients Collaborating with SARC for Ewing’s sarcoma Niraparib Initial Phase 1 data presented at the European Cancer Congress and 15th World Conference on Lung Cancer Continuing evaluation o
Slide 12: TSR-011: Significant Response and Stable Disease in Phase 1
All three evaluable ALK+ NSCLC patients remain on study (as of 15 Oct 2013): One RECIST Partial Response (PR) Two Non-RECIST PRs (investigator assessed) Long term SD observed in papillary thyroid, pancreatic cancer and colorectal cancer patients without ALK expression The most frequently occurring D
Slide 13: TRK gene rearrangements and TSR-011 binding and inhibition
TRK gene rearrangements have been found in several tumor types, including lung cancers (NSCLC and LCNEC) and papillary thyroid cancer TRK expression is involved with tumor aggressiveness, metastatic potential, perineural invasion and pain Tumor Type TRK Mutations Prevalence Secretory breast ETVG-TRK
Slide 14: Development Programs Update
Development Programs Update Phase 3 NOVA trial continues to enroll patients Phase 3 BRAVO trial now screening patients Collaborating with SARC for Ewing’s sarcoma Niraparib Initial Phase 1 data presented at the European Cancer Congress and 15th World Conference on Lung Cancer Continuing evaluation o
Slide 15: Rolapitant: Positive Phase 2 Results
Complete Response Rate (%) * Statistically significant 1 CR: Complete Response 2 ST: Standard Therapy Rolapitant: Positive Phase 2 Results p = 0.032* p = 0.001* p = 0.045* Patients Experiencing No Significant Nausea (%) p = 0.029* p = 0.026* p = 0.005*
Slide 16: Phase 3 Program Endpoints
Phase 3 Program Endpoints Primary Endpoint: Complete Response (CR): no emesis and no use of rescue medication Secondary Endpoints: No emesis; no significant nausea Captured in daily diary, patient records Degree of nausea on validated VAS scale Clinical Endpoints in combination with other antiemetic
Slide 17: Lonnie Moulder, Chief Executive Officer
November 7, 2013 Lonnie Moulder Chief Executive Officer
Slide 18: A Unique Therapeutic Profile
1 Based upon the secondary endpoint of “No Significant Nausea”; P3 data (netupitant) and the product label (aprepitant, fosaprepitant) and P2 data (rolapitant). 2 Emend is a registered trademark of Merck & Co., Inc. 3 Netupitant is being developed by Helsinn Healthcare A Unique Therapeutic Profile P
Slide 19: Established Guidelines Support Potential for NK-1 Market Growth
Source: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportive Established Guidelines Support Potential for NK-1 Market Growth HIGH EMETIC RISK INTRAVENOUS CHEMOTHERAPY – ACUTE AND DELAYED EMESIS PREVENTIONa,b,c Start before chemotherapyc,d Serotonin (5-HT3) antagonist:e,f Dolas
Slide 20: $1.5B U.S. Market Opportunity
1 A/C: anthracycline/cyclophosphamide $1.5B U.S. Market Opportunity Annual U.S. Opportunity: 5 Million “Day 1” Chemotherapy Administrations Approximately $300/Cycle Highly Emetogenic Regimens Moderately Emetogenic Regimens Cisplatin A/C1-based Lung Gynecological Genitourinary Head & Neck Others Brea
Slide 21: Commercial Organization Design
Commercial Organization Design Approximately 120 Total Headcount Opportunity for Significant Leverage
Slide 22: Proven Commercial Strategy in CINV
Proven Commercial Strategy in CINV Key Success Factors 1 3 2 4
Slide 23: Corporate Goals
Corporate Goals Initiated the Phase 3 trial of niraparib in ovarian cancer Presented niraparib Phase 1 data at ASCO Presented rolapitant DDI data at MASCC Begin the rolapitant IV dose finding and escalation study Present initial clinical data for TSR-011 at ECC Initiate patient treatment in the Phas
Slide 24: Third-Quarter Operating Results
Third-Quarter Operating Results November 7, 2013